Karyopharm Therapeutics Inc.
Symbol: KPTI
NASDAQ
1.37
USDMarkedspris i dag
-0.9064
P/E-forhold
-0.0160
PEG Ratio
157.64M
MRK Cap
- 0.00%
DIV Udbytte
Karyopharm Therapeutics Inc. (KPTI) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 897.57 | 192.1 | 278 | 228.6 | |||||||||||||
balance-sheet.row.short-term-investments | 636.07 | 139.2 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.net-receivables | 132.37 | 27 | 47.1 | 22.5 | |||||||||||||
balance-sheet.row.inventory | 13.65 | 3 | 4.2 | 4.1 | |||||||||||||
balance-sheet.row.other-current-assets | 226.73 | 11.8 | 19.8 | 2.9 | |||||||||||||
balance-sheet.row.total-current-assets | 1069.53 | 233.9 | 326.8 | 258.1 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 23.05 | 4.9 | 7.4 | 1.6 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-investments | 1.7 | 0.3 | 0.6 | 0.6 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.other-non-current-assets | 39.74 | 1.3 | 23.4 | 44.9 | |||||||||||||
balance-sheet.row.total-non-current-assets | 64.5 | 6.5 | 31.4 | 47.2 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.account-payables | 15.4 | 3.1 | 2.8 | 1.6 | |||||||||||||
balance-sheet.row.short-term-debt | 12.56 | 3.3 | 2.9 | 2.3 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 686.92 | 170.9 | 170.1 | 169.3 | |||||||||||||
Deferred Revenue Non Current | 530.39 | 132.5 | 132.7 | 133 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -395.13 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 172.27 | 63 | 60.3 | 0.7 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 1358.64 | 307.2 | 374.8 | 385 | |||||||||||||
balance-sheet.row.other-liabilities | -123.63 | 0 | -65.9 | -73.7 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 25.52 | 2.8 | 9 | 11.3 | |||||||||||||
balance-sheet.row.total-liab | 1487.05 | 376.6 | 374.8 | 385 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.05 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.retained-earnings | -5721 | -1487 | -1343.9 | -1178.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.1 | -0.2 | -0.6 | 0.2 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5370.03 | 1351 | 1327.9 | 1098.8 | |||||||||||||
balance-sheet.row.total-stockholders-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1134.03 | - | - | - | |||||||||||||
Total Investments | 636.37 | 139.5 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.total-debt | 696.11 | 177 | 173 | 169.3 | |||||||||||||
balance-sheet.row.net-debt | 434.6 | 124.1 | 37.8 | -21.2 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.6 | 0.8 | |||||||||||||
cash-flows.row.deferred-income-tax | 5.92 | -1.1 | 0 | 1.5 | |||||||||||||
cash-flows.row.stock-based-compensation | 21.71 | 21.7 | 35.4 | 29.8 | |||||||||||||
cash-flows.row.change-in-working-capital | 31.41 | 31.4 | -20 | -23.2 | |||||||||||||
cash-flows.row.account-receivables | 20.12 | 20.1 | -5.1 | -9.6 | |||||||||||||
cash-flows.row.inventory | 1.18 | 1.2 | -0.1 | -1.5 | |||||||||||||
cash-flows.row.account-payables | 0.35 | 0.3 | 1.2 | -2.8 | |||||||||||||
cash-flows.row.other-working-capital | -0.7 | 9.8 | -16 | -9.3 | |||||||||||||
cash-flows.row.other-non-cash-items | -9.19 | -2.2 | -0.3 | 8.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -92.72 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 104.3 | 5.5 | |||||||||||||
cash-flows.row.purchases-of-investments | -159.15 | -159.2 | -226 | -45.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 167.09 | 167.1 | 121.9 | 192.8 | |||||||||||||
cash-flows.row.other-investing-activites | -18.9 | 0 | -104.3 | -5.5 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 7.94 | 7.9 | -104.3 | 141.8 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -60 | |||||||||||||
cash-flows.row.common-stock-issued | 1.12 | 1.1 | 189.8 | 9.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 1.12 | 1.1 | 4 | 123.7 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 39.69 | 1.1 | 193.7 | 73.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.03 | 0 | -0.5 | 0 | |||||||||||||
cash-flows.row.net-change-in-cash | -83.61 | -83.4 | -60.6 | 108.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 264.86 | 52.9 | 136.9 | 197.4 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 348.48 | 136.3 | 197.4 | 89.1 | |||||||||||||
cash-flows.row.operating-cash-flow | -92.72 | -92.7 | -149.6 | -107.1 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.free-cash-flow | -92.72 | -92.7 | -149.7 | -112.8 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 146.03 | 146 | 157.1 | 209.8 | |||||||||||||
income-statement-row.row.cost-of-revenue | 5.02 | 5.5 | 5.2 | 3.4 | |||||||||||||
income-statement-row.row.gross-profit | 141.01 | 140.6 | 151.9 | 206.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 138.67 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 131.88 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.operating-expenses | 270.55 | 270.1 | 294.1 | 304.7 | |||||||||||||
income-statement-row.row.cost-and-expenses | 275.57 | 275.6 | 299.3 | 308.1 | |||||||||||||
income-statement-row.row.interest-income | 10.94 | 10.9 | 2.4 | 0.6 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.total-operating-expenses | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.58 | 0.5 | 2.3 | 0.5 | |||||||||||||
income-statement-row.row.ebitda-caps | -121.1 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -129.54 | -129.5 | -142.2 | -98.3 | |||||||||||||
income-statement-row.row.income-before-tax | -142.78 | -142.8 | -164.9 | -123.8 | |||||||||||||
income-statement-row.row.income-tax-expense | 0.32 | 0.3 | 0.4 | 0.3 | |||||||||||||
income-statement-row.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 |
Ofte stillede spørgsmål
Hvad er Karyopharm Therapeutics Inc. (KPTI) samlede aktiver?
Karyopharm Therapeutics Inc. (KPTI) samlede aktiver er 240438000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 69756000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.966.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -0.808.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -0.980.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -0.887.
Hvad er Karyopharm Therapeutics Inc. (KPTI) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -143099000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 177016000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 270101000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 52891000.000.